Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.

Readouts · Company page

Caregen

Company facts

Status: KOSDAQ 214370 · ISIN KR7214370009
Founded: 2001-08-23
CEO: 정용지
Headquarters: 서울특별시 강남구 역삼로98길 23 (대치동)
Industry: KSIC 211
Fiscal year end: 12
Links: Filings · DART · Quote · finance.naver.com · Website
Source: DART

Financial summary (from filings)

	2023	2024	2025
Revenue	79,210	82,586	72,808
Operating income	40,378	34,250	20,400
Net income	39,930	32,314	20,099
Total assets	247,277	240,697	231,273
Total liabilities	19,978	17,719	18,799
Total equity	227,299	222,978	212,475

Unit: KRW million · Consolidated statements · Source DART 사업보고서
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.

Readouts that mention this company

Readout 004Event 2026-06-23 · Read 2026-09-17Bio
A clinical trial has been published tracking for one year whether weight loss persists after switching from the injectable weight-loss drugs Wegovy and Mounjaro to the pill form of Foundayo · Eli Lilly paper review · Chugai Pharmaceutical Japanese patent · D&D Pharmatech, Ildong Pharmaceutical, Hanmi Pharmaceutical status

National R&D projects (NTIS)

item

7,140,792,000

Cumulative government R&D funding (KRW)

Largest projects

Korean patent filings (KIPRIS)

198

item

Recently published patents

Papers with affiliated authors (OpenAlex)

item

Papers by year

2025
3

Companies in the same readouts

Last updated 2026-09-21